News

Recent News

01/07/25

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

01/02/25

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

12/06/24

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

12/03/24

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

11/14/24

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Browse the press release archive

RSS Feeds
Email Alerts

Receive email alerts from Pacira

Sign up to automatically receive free Pacira BioSciences, Inc. financial information by email. Once signed up, you may choose from the following options;

Pacira BioSciences, Inc. SEC Filings Alert
Pacira BioSciences, Inc. News Alert

You may change your email options ar any time, or opt out if desired.

Sign up for email alerts

LinkedIn
X
YouTube

EXPAREL^® (bupivacaine liposome injectable suspension), ioveraº, ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), and Pacira are registered trademarks of the respective subsidiaries of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.

Contact
Legal
Sitemap
Privacy Notice
Terms of Use
Accessibility Statement